Navigation Links
Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
Date:6/2/2008

who have failed standard hormonal therapies. The dose-expansion study has enrolled 84 patients in three cohorts (60, 150, 240 mg/day) to date. Dr. Scher's presentation covered PSA data from all patients who have been followed for at least 12 weeks, the standard minimum duration of observation used to assess the treatment effects of prostate cancer drugs. Of the 42 chemo-naive and 31 post-chemotherapy evaluable patients across the three dose levels, 23 patients (55 percent) and 13 patients (42 percent) showed PSA declines greater than 50 percent at week 12 compared to baseline, respectively. Of the 28 evaluable patients from the 240 mg/day dose group of the trial, eight patients (29 percent) experienced a decline in PSA levels of greater than 90 percent compared to 9 percent and 13 percent in the 60 mg/day and 150 mg/day dose groups, respectively.

The number of CTC in a blood sample from a prostate cancer patient can indicate prognosis; patients with higher CTC counts (greater than or equal to five) are thought to have less favorable prognoses. MDV3100 treatment preserved favorable prognosis CTC counts below five in 92 percent of patients in the 60 and 150 mg/day dose groups and converted CTC counts from unfavorable to favorable prognoses in 33 percent of patients in the 60 mg/day dose group and in 56 percent of patients in the 150 mg/day dose group, respectively.

Importantly, radiographic data from both the 60 mg/day and 150 mg/day dosing cohorts showed stabilization of disease through 12 weeks of treatment. Of the 15 evaluable patients with soft tissue disease, 12 patients (80 percent) had stabilization of disease. Prior to enrollment in this study, all these patients had progressive disease despite standard-of-care hormonal therapies, and in roughly half the patients, also chemotherapy. As opposed to most previous studies in CRPC that have used the RECIST criteria to define evaluable patients and assess radiographic changes, the MDV3100 data were ana
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
2. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
3. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
4. Medivations Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimers Disease Patients, Resulting in Reduced Caregiver Distress
5. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
6. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
7. IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients
8. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
9. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
10. Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer
11. Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Aug. 28, 2014 /PRNewswire-iReach/ -- Gateway Analytical announced ... 9 th Annual Global Pharma Manufacturing Summit ... 8-9 th . The Global Pharma Manufacturing Summit ... small molecule and biologic pharmaceutical manufacturing. The conference ... today,s manufacturers face, such as the increasing pressure ...
(Date:8/28/2014)... , Aug. 28, 2014  Robotic surgery is ... media, both for the promise of improved outcomes ... quick deployment of surgical robots and market pressures ... facilities to evaluate their robotic surgery training programs ... team.    ECRI Institute ( www.ecri.org ...
(Date:8/28/2014)... THOUSAND OAKS, Calif. , Aug. 28, 2014 /PRNewswire/ ... the submission of a Biologics License Application (BLA) to ... seeking approval for the treatment of high cholesterol. Evolocumab ... proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that ... (LDL-C), or "bad" cholesterol, from the blood. 1 ...
Breaking Medicine Technology:Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 2Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 3Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 2Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 3Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 4Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 5Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 2Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 3Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 4Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 5Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 6Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 7Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 8Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA 9
... Mass. , July 26 The Exergen ... nationwide that stock the Exergen TemporalScanner™, according to data ... of all types of thermometers, including national brands and ... found Exergen came out on top. Exergen,s retail unit ...
... , NEWARK, Del. and GRONINGEN, Netherlands ... a leading full-service GLP/GCP-compliant contract research organization providing testing ... announced the completion of its acquisition of Xendo Drug ... .  XDD, a European contract research organization (CRO), will ...
Cached Medicine Technology:Exergen TemporalScanner Thermometer Best Selling Brand at Retailers 2QPS Announces the Acquisition of Xendo Drug Development 2QPS Announces the Acquisition of Xendo Drug Development 3QPS Announces the Acquisition of Xendo Drug Development 4
(Date:8/28/2014)... 2014 Millennium Treatment Group is ... This month will be a celebration of the ... services. Along with other treatment facilities and mental ... spread the word about this national observance. , ... work of treatment and recovery professionals, and has ...
(Date:8/28/2014)... FL (PRWEB) August 28, 2014 Millennium ... use affecting users in the workplace. A recent ... Dependence (NCADD) states that drug abuse is costing ... who use or are addicted to drugs affect their ... activities carry over into the workplace, causing expensive problems ...
(Date:8/28/2014)... HealthDay Reporter THURSDAY, Aug. 28, 2014 ... worsen symptoms of multiple sclerosis (MS), a new study from ... vitamin D, smoking and Epstein Barr virus infection. Our study ... affecting MS patients," said lead researcher Dr. Mauricio Farez, of ... Multiple sclerosis is a disease of the nervous system ...
(Date:8/28/2014)... York, New York (PRWEB) August 28, 2014 ... second federal bellwether trial of a transvaginal mesh ... by Ethicon, Inc., Bernstein Liebhard LLP reports. Court ... District of West Virginia indicate that the case ... had to undergo two revision surgeries, allegedly due ...
(Date:8/28/2014)... August 28, 2014 Allegheny ... today a regional partnership designed to advance sports ... for competitive young athletes, scholastic athletes and their ... Strong Body & Mind Initiative will offer a ... the physical and mental dynamics involved in pursuing ...
Breaking Medicine News(10 mins):Health News:Millennium Treatment Group Celebrates National Recovery Month 2Health News:Drug Use Causes Problems in the Workplace 2Health News:Could Too Much Salt Harm MS Patients? 2Health News:Could Too Much Salt Harm MS Patients? 3Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 2Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 3Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 4
... N.C., Nov. 2 Just how much of the time,that ... due to,administrative tasks and internal communication? Pharmaceutical sales directors ... of the time used for internal communication - or 6 ... in lost sales every year,according to a recent research study ...
... HILL, N.C., Nov. 2 Records and Information,Management ... in the success of,their parent organizations through reducing ... Today the programs account for,over $1.5 million in ... leader,Best Practices, LLC. This number will continue ...
... each point scored, CENTENNIAL, Colo., Nov. 2 ... show support for their favorite team -- camping,out for ... for the big game. Now five football teams are ... of a deadly disease --,prostate cancer. The Denver ...
... Inc.,(Nasdaq: IDMI ) today announced the presentation of ... patients,with lung metastases as a result of the progression ... typically affects children and young,adults. The data show that ... exhibited signs of disease control. "These results are ...
... Indevus,Pharmaceuticals, Inc. (Nasdaq: IDEV ) today announced ... for review the Company,s New Drug,Application (NDA) for NEBIDO(R), ... hypogonadism. The FDA Prescription,Drug User Fee Act (PDUFA) target ... was submitted to the FDA by the Company on ...
... Corporation,(Nasdaq: MNKD ), focused on discovering, developing and commercializing,treatments ... at,the following conferences: * The Acumen BioFin Rodman & ... November 6, 2007 at 2:20 PM ET at the New ... * The CIBC 18th Annual Healthcare Conference on Wednesday ...
Cached Medicine News:Health News:New Pharmaceutical Sales Force Communication Metrics: Nearly 6 Weeks of Sales Time per Rep Wasted Each Year 2Health News:New Records & Information Management: Are You Spending Right on Records Management, Data Security and Compliance? 2Health News:Professional Football Takes the Field to Tackle Prostate Cancer 2Health News:Professional Football Takes the Field to Tackle Prostate Cancer 3Health News:IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program 2Health News:IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program 3Health News:IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program 4Health News:IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program 5Health News:IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program 6Health News:IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program 7Health News:FDA Accepts New Drug Application for NEBIDO(R) Submitted by Indevus 2Health News:FDA Accepts New Drug Application for NEBIDO(R) Submitted by Indevus 3Health News:FDA Accepts New Drug Application for NEBIDO(R) Submitted by Indevus 4
... Introducing the new PRONEB® ULTRA compressor. ... treatment time while delivering more medication to ... PARI LC PLUS® or PARI LC STAR® ... are optimized for inhalation and retention into ...
... Compressed Air., ,Allied Healthcares Timeter® PCS 414 ... other air compressors that you may wonder if ... PCS 414 features a durable, mar-resistant steel case ... unit weighs only 26.5 pounds. The PCS 414 ...
... DC powered compressor nebulizer system available. ... to take nebulizer treatments away from ... the included AC power adapter or ... The integral reusable jet nebulizer kit ...
The 45 PSI SuperSportNeb provides superior performance that translates to shorter treatment times. Like the SportNeb, it is constructed with die-cast aluminum compressor components for consistent rel...
Medicine Products: